Wyatt Group is a science-led company pioneering the next generation of oral cannabis and psychedelic therapeutics. Our core mission is to develop clinically validated, precision-dosed formulations that meet the highest pharmaceutical standards, targeting increasing needs in neurology, psychiatry, and chronic disease management.

Our co-founders bring decades of legacy, legal and pharma experience in the international cannabis, pharmaceuticals, consumer goods and agricultural industries, boasting a robust expert and commercial network that spans the globe. Their expertise lies in navigating compliance and pioneering new products and territories.